Tyck till om SwePub Sök
här!
Search: WFRF:(Stattin Pär)
> Bill Axelson Anna
> Gedeborg Rolf >
A drug comorbidity ...
A drug comorbidity index to predict mortality in men with castration resistant prostate cancer
-
- Fallara, Giuseppe (author)
- Uppsala universitet,Urologkirurgi,IRCCS Osped San Raffaele, Div Expt Oncol, Unit Urol URI, Milan, Italy.;Univ Vita Salute San Raffaele, Milan, Italy.
-
- Gedeborg, Rolf (author)
- Uppsala universitet,Anestesiologi och intensivvård
-
- Bill-Axelson, Anna (author)
- Uppsala universitet,Urologkirurgi
-
show more...
-
- Garmo, Hans (author)
- Uppsala universitet,Institutionen för kirurgiska vetenskaper,Uppsala Univ Hosp, Reg Canc Ctr, Uppsala Örebro, Uppsala, Sweden.
-
- Stattin, Pär (author)
- Uppsala universitet,Urologkirurgi
-
show less...
-
(creator_code:org_t)
- 2021-07-28
- 2021
- English.
-
In: PLOS ONE. - : Public Library of Science (PLoS). - 1932-6203. ; 16:7
- Related links:
-
https://doi.org/10.1...
-
show more...
-
https://uu.diva-port... (primary) (Raw object)
-
https://journals.plo...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Background The Charlson Comorbidity Index is a poor predictor of mortality in men with castration resistant prostate cancer (CRPC). To improve this prediction, we created a comorbidity index based on filled prescriptions intended to be used in registry-based studies. Materials and methods In a population-based cohort of men with CPRC a drug comorbidity index (DCI-CRPC) was calculated based on prescriptions filled during a 365-day period before the date of CRPC diagnosis to predict mortality. Five risk categories for men with CRPC were defined based on PSA kinetics. Mortality rates were described by Kaplan-Meier curves. The predictive ability of the DCI-CRPC was compared in univariable models to that of the original DCI, derived from men in the general population, and to that of the Charlson Comorbidity Index. Results In 1,885 men with CRPC the median overall survival ranged from 3.0 years (95% confidence interval [CI] 2.8 to 3.4) in the first tertile of the DCI-CRPC, to 1.0 year (95% CI 0.9 to 1.1) in the third tertile of the DCI-CRPC. The index had higher discriminative ability (C-index 0.667) than the Charlson Comorbidity Index (C-index 0.508). The discriminative ability of the DCI-CRPC was highest in the subgroup with least aggressive cancer (C-index 0.651) and lowest in men with most aggressive cancer (C-index 0.618). The performance of the DCI-CRPC was comparable to that of the original DCI. Conclusion Our newly created comorbidity index using filled prescriptions predicted death in men with CRPC better than the Charlson Comorbidity Index.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
-
PLOS ONE
(Search for host publication in LIBRIS)
To the university's database